A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis — Cielo  

LGI1 Autoimmune Encephalitis Clinical Trial

Official title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Basket Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis

Status Recruiting

Clinical Trial Summary

The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab in participants with anti-N-methyl-D-aspartic acid receptor (NMDAR) and anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Autoimmune Diseases of the Nervous System
• Encephalitis
• Epilepsies, Partial
• Hashimoto Disease

• NCT number: NCT05503264
• Study type: Interventional
• Source: Hoffmann-La Roche
• Contact: Reference Study ID Number: WN43174, https://forpatients.roche.co
• Phone: 888-662-6728 (U.S.)
• Email: global-roche-genentech-trials@gene.com
• Status: Recruiting
• Phase: Phase 3
• Start date: September 27, 2022
• Completion date: December 7, 2027